JMAC vs. KROS, SAGE, ORGO, VALN, ARCT, ZVRA, CMPX, ATXS, TRML, and CDXC
Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Keros Therapeutics (KROS), Sage Therapeutics (SAGE), Organogenesis (ORGO), Valneva (VALN), Arcturus Therapeutics (ARCT), Zevra Therapeutics (ZVRA), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), Tourmaline Bio (TRML), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry.
Maxpro Capital Acquisition vs.
Keros Therapeutics (NASDAQ:KROS) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
In the previous week, Keros Therapeutics had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 3 mentions for Keros Therapeutics and 0 mentions for Maxpro Capital Acquisition. Keros Therapeutics' average media sentiment score of 0.17 beat Maxpro Capital Acquisition's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media.
Maxpro Capital Acquisition has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Maxpro Capital Acquisition's return on equity of 0.00% beat Keros Therapeutics' return on equity.
Keros Therapeutics presently has a consensus price target of $52.56, suggesting a potential upside of 377.78%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Keros Therapeutics is more favorable than Maxpro Capital Acquisition.
Keros Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.
71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Maxpro Capital Acquisition has lower revenue, but higher earnings than Keros Therapeutics.
Keros Therapeutics received 61 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users.
Summary
Keros Therapeutics beats Maxpro Capital Acquisition on 9 of the 13 factors compared between the two stocks.
Get Maxpro Capital Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maxpro Capital Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:JMAC) was last updated on 2/5/2025 by MarketBeat.com Staff
Free JMAC Stock Alerts